Ψ-2C-DFMO

Ψ-2C-DFMO, also known as ψ-2C-O-35 or as 4-difluoromethoxy-2,6-dimethoxyphenethylamine, is a psychedelic drug of the phenethylamine and ψ-phenethylamine families. It is the phenethylamine analogue of ψ-DODFMO and is also structurally related to other psychedelics like difluoromescaline and 2C-T-35. The drug has been found to be active at a dose of 17mg orally, with moderately intense effects and a relatively long duration of around 18hours. Ψ-2C-DFMO was first described in the scientific literature by Daniel Trachsel in 2012. It is a controlled substance in Canada under phenethylamine blanket-ban language.